Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.
Company profile
Ticker
TLGTQ, TLGTQ
Exchange
Website
CEO
Timothy Sawyer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IGI INC, IGI LABORATORIES, INC
SEC CIK
Corporate docs
Subsidiaries
Igen, Inc • Teligent Pharma, Inc. • Teligent Luxembourg S.a.r.l. • Teligent Canada, Inc. • TELIP, LLC • Microburst Energy, Inc. • Blood Cells, Inc. • Flavorsome, Ltd. • Teligent Jersey Limited ...
IRS number
10355758
TLGTQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
27 Oct 21
8-K
Entry into a Material Definitive Agreement
15 Oct 21
8-K
Departure of Directors or Certain Officers
27 Sep 21
8-K
Material Modifications to Rights of Security Holders
24 Sep 21
10-Q
2021 Q2
Quarterly report
16 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
22 Jul 21
DEFA14A
Additional proxy soliciting materials
30 Jun 21
DEFA14A
Additional proxy soliciting materials
21 Jun 21
10-Q
2021 Q1
Quarterly report
24 May 21
DEF 14A
Definitive proxy
19 May 21
Transcripts
TLGTQ
Earnings call transcript
2021 Q2
16 Aug 21
TLGTQ
Earnings call transcript
2021 Q1
25 May 21
TLGTQ
Earnings call transcript
2020 Q2
19 Aug 20
TLGTQ
Earnings call transcript
2020 Q1
22 May 20
TLGTQ
Earnings call transcript
2019 Q4
8 Apr 20
TLGTQ
Earnings call transcript
2019 Q3
4 Nov 19
TLGTQ
Earnings call transcript
2019 Q2
5 Aug 19
TLGTQ
Earnings call transcript
2019 Q1
6 May 19
TLGTQ
Earnings call transcript
2018 Q4
18 Mar 19
TLGTQ
Earnings call transcript
2018 Q3
14 Nov 18
Latest ownership filings
Financial summary
Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm |
Cash burn (monthly) | 1.64 mm | (no burn) | 3.56 mm | 11.43 mm | 2.18 mm | 1.92 mm |
Cash used (since last report) | 55.10 mm | n/a | 119.49 mm | 384.15 mm | 73.28 mm | 64.53 mm |
Cash remaining | -31.71 mm | n/a | -96.09 mm | -360.76 mm | -49.89 mm | -41.14 mm |
Runway (months of cash) | -19.3 | n/a | -27.0 | -31.6 | -22.9 | -21.4 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|